Estrella Immunopharma, Inc. (NASDAQ:ESLA) Sees Significant Decrease in Short Interest

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the recipient of a significant drop in short interest during the month of February. As of February 27th, there was short interest totaling 638,651 shares, a drop of 12.0% from the February 12th total of 725,979 shares. Based on an average daily volume of 39,381 shares, the short-interest ratio is presently 16.2 days. Currently, 3.8% of the shares of the company are sold short. Currently, 3.8% of the shares of the company are sold short. Based on an average daily volume of 39,381 shares, the short-interest ratio is presently 16.2 days.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Wall Street Zen upgraded Estrella Immunopharma from a “sell” rating to a “hold” rating in a research note on Saturday, January 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Estrella Immunopharma in a report on Wednesday, January 28th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $8.00 price objective on shares of Estrella Immunopharma in a research report on Monday, February 9th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $8.00.

Estrella Immunopharma Trading Down 7.1%

Shares of ESLA opened at $1.17 on Tuesday. The firm has a market cap of $44.19 million, a P/E ratio of -3.44 and a beta of 0.53. Estrella Immunopharma has a 12 month low of $0.73 and a 12 month high of $3.15. The stock’s 50 day moving average is $1.16 and its two-hundred day moving average is $1.50.

Institutional Investors Weigh In On Estrella Immunopharma

A number of institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC raised its position in Estrella Immunopharma by 1,045.7% during the fourth quarter. Renaissance Technologies LLC now owns 122,468 shares of the company’s stock worth $191,000 after acquiring an additional 111,779 shares during the period. Geode Capital Management LLC lifted its holdings in Estrella Immunopharma by 8.2% during the fourth quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock valued at $171,000 after purchasing an additional 8,318 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Estrella Immunopharma in the fourth quarter valued at about $88,000. XTX Topco Ltd increased its stake in shares of Estrella Immunopharma by 376.9% during the fourth quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock worth $77,000 after purchasing an additional 39,099 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Estrella Immunopharma by 93.5% during the fourth quarter. State Street Corp now owns 43,252 shares of the company’s stock worth $67,000 after purchasing an additional 20,900 shares in the last quarter. Institutional investors and hedge funds own 0.35% of the company’s stock.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.